Trump Pushes Cannabis Rescheduling Amid Federal Court Hemp CMS Issues
Cannabis rescheduling federal court impact is reshaping the research landscape by addressing legal and regulatory challenges. Federal court cases involving hemp CMS issues highlight ongoing uncertainties affecting clinical research. This shift could…
US System For Classifying Marijuana And Other Drugs Does ‘Immense Damage,’ Former DEA Official Says
The controlled substances act scheduling system critically affects marijuana research and patient access. Former DEA officials highlight how this system creates barriers to clinical practice. Understanding these impacts is essential for anticipating…
Regulatory Digest: Marijuana Rescheduling and Clinical Research
Marijuana rescheduling clinical research is a pivotal topic in 2026 regulatory updates. This shift could enable expanded clinical trials and evidence-based cannabis therapeutics. Understanding these changes is essential for clinicians and researchers…